All Pharma News
price-trendAsk Us
Neurimmune to regain rights to brain amyloid depleter for Alzheimer™s disease

Neurimmune to regain rights to brain amyloid depleter for Alzheimer™s disease
GLOBENEWSWIRE
31 Jan 2024
Share Share
Neurimmune to preset results of phase 1b proof-of-concept study of NI006

Neurimmune to preset results of phase 1b proof-of-concept study of NI006
PHARMABIZ
19 May 2023
Share Share
Biogen CEO points to risk in neuroscience as 3 programs cut

Biogen CEO points to risk in neuroscience as 3 programs cut
Annalee Armstrong FIERCEBIOTECH
21 Jul 2022
Share Share
AstraZeneca, Swiss firm Neurimmune ink $760 million deal for antibody drug

AstraZeneca, Swiss firm Neurimmune ink $760 million deal for antibody drug
Pushkala Aripaka REUTERS
01 Mar 2022
Share Share
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical

Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
PRNEWSWIRE
17 Jan 2022
Share Share
FDA Approval of Aducanumab

FDA Approval of Aducanumab
PRNEWSWIRE
07 Jun 2021
Share Share
Neurimmune Announces the Initiation of a Phase 1 Study of NI006

Neurimmune Announces the Initiation of a Phase 1 Study of NI006
PR NEWSWIRE
27 Feb 2020
Share Share